Related Experiment Video
Updated: Apr 13, 2026

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
Cardiac magnetic resonance left atrioventricular coupling index as a prognostic tool in hypertrophic cardiomyopathy
Jinyang Wen1, Junhao Tu2, Xinwei Tao3
1Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Insights
The novel left atrioventricular coupling index (LACI) effectively predicts adverse outcomes in hypertrophic cardiomyopathy (HCM) patients. This cardiac MRI marker is superior to traditional measures for identifying high-risk individuals.
Area of Science:
- Cardiology
- Cardiovascular Imaging
- Biomarker Discovery
Background:
- The left atrioventricular coupling index (LACI) is a novel marker associated with cardiovascular events in general populations.
- Limited research exists on cardiac magnetic resonance (CMR)-derived LACI in hypertrophic cardiomyopathy (HCM) patients.
- The prognostic value of LACI in HCM requires further thorough investigation.
Purpose of the Study:
- To explore the association between LACI and adverse clinical outcomes in patients with HCM.
- To evaluate the prognostic value of CMR-derived LACI in HCM.
- To compare the predictive performance of LACI against conventional parameters.
Main Methods:
- Retrospective enrollment of 206 HCM patients who underwent CMR examination.
- LACI calculated as the ratio of left atrial (LA) to left ventricular (LV) volumes at LV end-diastole.
- Composite endpoint included death, heart failure, and arrhythmia events; multivariable Cox regression and ROC analysis were employed.
Main Results:
- LACI was identified as an independent predictor of composite events in HCM patients (HR 1.054, P < 0.001) after adjusting for age and atrial fibrillation.
- An optimal LACI cut-off of 40.09% was determined for risk stratification.
- Integrating LACI into a clinical model significantly improved risk prediction (C-statistic 0.892, NRI 0.627, IDI 0.295) compared to LA diameter, LAEF, LAVI, and LGE extent.
Conclusions:
- LACI is an independent risk factor for adverse clinical outcomes in HCM patients.
- LACI demonstrates superior performance in identifying high-risk HCM patients compared to conventional LA parameters and late gadolinium enhancement (LGE) extent.
- CMR-derived LACI holds significant prognostic value in HCM.
Aims:
A novel marker left atrioventricular coupling index (LACI) has been proved to be associated with cardiovascular events in patients without history of cardiovascular disease. However, the studies on cardiac magnetic resonance-derived LACI in hypertrophic cardiomyopathy (HCM) patients are limited, and the prognostic value of LACI has still not been studied thoroughly, so we aimed to explore the association between LACI and adverse clinical outcomes in HCM patients.
Methods:
A total of 206 HCM patients underwent cardiac magnetic resonance examination were retrospectively enrolled. LACI is defined by the ratio between the left atrial (LA) volume and the left ventricular (LV) volume in LV end-diastolic phase. The composite endpoint was categorized into death-related, heart failure-related, and arrhythmia-related events, reflecting mortality risk, heart failure progression, and arrhythmia burden, respectively. Receiver operating characteristics curve analysis was used to determine the optimal cut-off value for LACI to distinguish HCM patients at high risk of adverse clinical outcome. Multivariable Cox regression models were built including significant clinical variables, LA ejection fraction (LAEF), LA volume index (LAVI), late gadolinium enhancement (LGE) extent and LACI. The improvement of discrimination by adding LACI to a clinical model was assessed using C-statistic, net reclassification improvement (NRI) and integrated discrimination improvement (IDI).
Results:
Thirty-four HCM patients reached the endpoint during a median follow-up time of 60 [interquartile range (50-68)] months. In the multivariate Cox regression analysis, LACI [hazard ratio 1.054, 95% confidence interval (CI): 1.037, 1.071; P < 0.001] was an independent predictor of the composite events after adjustment for age and atrial fibrillation. Then 40.09% was identified as an optimal cut-off for LACI in the risk stratification. Integrating LACI to the clinical model yielded higher C-statistic 0.892 with 95% CI (0.861, 0.922) compared with LA diameter, LAEF, LAVI and LGE extent, providing an improvement in prediction of high-risk patients (NRI = 0.627, 95% CI: 0.112-0.934; IDI = 0.295, 95% CI: 0.016-0.709).
Conclusions:
LACI is an independent risk factor for clinical adverse outcome and is superior to conventional LA parameters and LGE extent for the identification of high-risk HCM patients.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
08:10Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Related Concept Videos
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Stenosis II: Clinical features and Diagnostic Tests
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care